2009

2009

2009

April 18, 2009

Letter from HSCI Scientific Directors

March 9, 2009

Dear friends and colleagues,

Today marks the beginning of a new era in our quest to unlock the full capacity of stem cells to develop treatments and cures for diseases and conditions that plague humankind.

MGH establishes new express quarantine policy for importing mice from the GMF

April 17, 2009

HSCI investigators at MGH will now have expedited access to mouse models made by the Genome Modification Facility (GMF). This is what Steven Niemi, DVM, Director of the Center for Comparative Medicine (CCM) at MGH announced in a recent email after completing an extensive review of the pathogen monitoring process at the Harvard facilities and the GMF. By adopting the Express Quarantine process, MGH will move GMF mice into their barrier facilities by 6 weeks of age, which effectively will eliminate any delays in setting up research colonies.

HSCI comments on NIH Draft guidelines for Human Embryonic Stem Cell Research

May 21, 2009

n response to President Obama’s Executive Order 13505: Removing Barriers to Responsible Scientific Research Involving Human Stem Cells, on April 23rd the NIH released Draft Guidelines for funding of research involving human embryonic stem cell lines.  HSCI has submitted a comment letter to the NIH, which can be seen

Konrad Hochedlinger, PhD, receives the ISSCR Outstanding Young Investigator Award

July 10, 2009

HSCI Principal Faculty member Konrad Hochedlinger, PhD, received the ISSCR Outstanding Young Investigator Award at the ISSCR 7th Annual Meeting in Barcelona. The award, which recognizes the exceptional achievements of an investigator in the early part of his or her independent career in stem cell research, includes a $7,500 personal award and complimentary registration to the ISSCR Annual Meeting where he was honored.

HSCI invites applications for seed grants

December 7, 2009

The Harvard Stem Cell Institute (HSCI) invites applications for seed grants funding.  The purpose of this program is to provide early funding for innovative projects in the field of stem cell research including basic, translational and clinical research.